Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines

Pancreaticobiliary cancer, encompassing malignancies of both the pancreatic and biliary tract, presents a formidable clinical challenge marked by a uniformly bleak prognosis. The asymptomatic nature of its early stages often leads to delayed detection, contributing to an unfavorable 5-year overall s...

Full description

Saved in:
Bibliographic Details
Main Authors: Nawal Amhis, Julie Carignan, Lee-Hwa Tai
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:Molecular Therapy: Oncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2950329924000675
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850129890665299968
author Nawal Amhis
Julie Carignan
Lee-Hwa Tai
author_facet Nawal Amhis
Julie Carignan
Lee-Hwa Tai
author_sort Nawal Amhis
collection DOAJ
description Pancreaticobiliary cancer, encompassing malignancies of both the pancreatic and biliary tract, presents a formidable clinical challenge marked by a uniformly bleak prognosis. The asymptomatic nature of its early stages often leads to delayed detection, contributing to an unfavorable 5-year overall survival rate. Conventional treatment modalities have shown limited efficacy, underscoring the urgent need for alternative therapeutic approaches. In recent years, immunotherapy has emerged as a promising avenue in the fight against pancreaticobiliary cancer. Strategies such as therapeutic vaccines and the use of tumor-infiltrating lymphocytes have garnered attention for their potential to elicit more robust and durable responses. This review seeks to illuminate the landscape of emerging immunotherapeutic interventions, offering insights from both clinical and research perspectives. By deepening our understanding of pancreaticobiliary cancer and exploring innovative treatment modalities, we aim to catalyze improvements in patient outcomes and quality of life.
format Article
id doaj-art-f1e8d74ee24545918f4e91eae17b6659
institution OA Journals
issn 2950-3299
language English
publishDate 2024-09-01
publisher Elsevier
record_format Article
series Molecular Therapy: Oncology
spelling doaj-art-f1e8d74ee24545918f4e91eae17b66592025-08-20T02:32:49ZengElsevierMolecular Therapy: Oncology2950-32992024-09-0132320082510.1016/j.omton.2024.200825Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccinesNawal Amhis0Julie Carignan1Lee-Hwa Tai2Department of Immunology and Cell Biology, Université de Sherbrooke, Sherbrooke, QC J1E 4K8, Canada; Department of Surgery, Division of General Surgery, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, CanadaCentre de Recherche du CHUS, Sherbrooke, QC J1H 5N4, CanadaDepartment of Immunology and Cell Biology, Université de Sherbrooke, Sherbrooke, QC J1E 4K8, Canada; Centre de Recherche du CHUS, Sherbrooke, QC J1H 5N4, Canada; Corresponding author: Lee-Hwa Tai, Department of Immunology and Cell Biology, Université de Sherbrooke, Sherbrooke, QC J1E 4K8, Canada.Pancreaticobiliary cancer, encompassing malignancies of both the pancreatic and biliary tract, presents a formidable clinical challenge marked by a uniformly bleak prognosis. The asymptomatic nature of its early stages often leads to delayed detection, contributing to an unfavorable 5-year overall survival rate. Conventional treatment modalities have shown limited efficacy, underscoring the urgent need for alternative therapeutic approaches. In recent years, immunotherapy has emerged as a promising avenue in the fight against pancreaticobiliary cancer. Strategies such as therapeutic vaccines and the use of tumor-infiltrating lymphocytes have garnered attention for their potential to elicit more robust and durable responses. This review seeks to illuminate the landscape of emerging immunotherapeutic interventions, offering insights from both clinical and research perspectives. By deepening our understanding of pancreaticobiliary cancer and exploring innovative treatment modalities, we aim to catalyze improvements in patient outcomes and quality of life.http://www.sciencedirect.com/science/article/pii/S2950329924000675MT: Regular IssueImmunologygastrointestinal cancerpancreas ductal adenocarcinomacholangiocarcinomacancer vaccine
spellingShingle Nawal Amhis
Julie Carignan
Lee-Hwa Tai
Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines
Molecular Therapy: Oncology
MT: Regular Issue
Immunology
gastrointestinal cancer
pancreas ductal adenocarcinoma
cholangiocarcinoma
cancer vaccine
title Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines
title_full Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines
title_fullStr Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines
title_full_unstemmed Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines
title_short Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines
title_sort transforming pancreaticobiliary cancer treatment exploring the frontiers of adoptive cell therapy and cancer vaccines
topic MT: Regular Issue
Immunology
gastrointestinal cancer
pancreas ductal adenocarcinoma
cholangiocarcinoma
cancer vaccine
url http://www.sciencedirect.com/science/article/pii/S2950329924000675
work_keys_str_mv AT nawalamhis transformingpancreaticobiliarycancertreatmentexploringthefrontiersofadoptivecelltherapyandcancervaccines
AT juliecarignan transformingpancreaticobiliarycancertreatmentexploringthefrontiersofadoptivecelltherapyandcancervaccines
AT leehwatai transformingpancreaticobiliarycancertreatmentexploringthefrontiersofadoptivecelltherapyandcancervaccines